Acute Disease ; Humans ; Interleukins ; blood ; Leukemia, Myeloid, Acute ; blood

No abstract available.
Acute Coronary Syndrome* ; Blood Platelets* ; Glycoproteins*

In 2001-2002 period, at the Hospital of Hemotology and Blood Transfusion of Ho Chi Minh, a cross-sectioncal analytic descriptive study was carried out covering 92 cases thrombocyte transfusion for 67 patients with acute myoblastic and lymphoblastic leucemia. The results were analogue with those obstained by foreign authors concerning the indices of assessment of the efficacy of thrombocyte transfusion. The number of thrombocytes in a condensed unit of blood plaquettes obtained on the apparatus of extraction and isolation in comparing with body weight of Viet Nam subject had created optimal doses of thrombocyte transfusion in patients without associated factors increasing the consumption of blood plaquettes and these are the doses possibly attained in Vietnamese blood donor
Leukemia, Lymphocytic, Acute ; Platelet Transfusion ; Blood

BACKGROUNDSeveral studies investigating the prognostic utility of interleukin-10 (IL-10) in patients with acute coronary syndrome (ACS) have provided conflicting findings. The aim of the study was to assess the existing evidence regarding association between serum IL-10 levels and adverse events.

METHODSLiterature search was performed in PubMed, EMBASE, and Cochrane Trials Register databases from their inception to September 30, 2012. In addition, reference lists of the included articles and their related citations in PubMed were also reviewed for additional pertinent studies.

RESULTSA total of 12 eligible studies comprising a total of 5882 patients were identified. The pooled relative risks for both studies reporting the risk estimates by IL-10 categories and studies reporting the risk estimates by unit IL-10 indicated an association between high IL-10 levels and adverse events. Sensitivity and subgroup analysis indicated that the results obtained in IL-10 categories were not stable.

CONCLUSIONSData from our meta-analysis supported the existence of a relationship between high serum IL-10 levels and adverse events in patients with ACS. Large study with longer follow-up is needed to confirm the findings.

Acute Coronary Syndrome ; blood ; Humans ; Interleukin-10 ; blood

OBJECTIVE: To analyze and compare the effects of leukapheresis on hemostatic function in patients with hyperleukocytic leukemia. METHODS: A total of 139 patients with AML, ALL and CML who underwent leukapheresis from June 2009 to February 2020 and did coagulation test before and after operation were included in this study. The clearance efficiency of each group and the difference among three groups were evaluated, as well as hemostatic function including platelet counts, coagulation indicators, CDSS score and incidence of adverse events. The difference of hemostatic function caused by leukapheresis in different leukemia patients were compared. RESULTS: After leukapheresis, the WBC counts were decreased significantly in the three groups of patients (P<0.001), and the clearance efficiency was highest in ALL patients. However, the platelet counts also were decreased significantly (AML:P＜0.001, ALL: P＜0.001, CML: P＜0.01) in the three groups of patients, particularly for acute leukemia patients with a positive correlation with WBC clearance efficiency(r=0.284). After leukapheresis, fibrinogen decreased, PT and APTT prolonged. For acute leukemia patients, higher CDSS score was related to an elevated incidence of bleeding events (P<0.05). CONCLUSION Leukapheresis is an effective method to decrease the leukemic burden, but it is necessary to monitor the impact on hemostatic function. It is recommended to assess the CDSS socre for acute leukemia patients, in order to identify the predictive value for bleedings.
Acute Disease ; Blood Coagulation ; Blood Coagulation Tests ; Hemorrhage ; Hemostatics ; Humans ; Leukapheresis/methods* ; Leukemia, Myeloid, Acute/therapy*

OBJECTIVETo investigate the relationship between blood nitrogen monoxide(NO) and PaO2 or PaCO2 levels in patients with severe and moderate acute carbon monoxide poisoning.

METHODThe blood levels of NO in patients with severe and moderate acute carbon monoxide poisoning was assayed with nitrate reductase method, and its correlation with the blood levels of PaO2 and PaCO2 was analyzed.

RESULTSThe blood level of NO in patients with severe and moderate acute carbon monoxide poisoning were (36.6 +/- 9.9) and (35.7 +/- 10.7) mumol/L respectively, significantly lower than that of control group[(64.9 +/- 14.3) mumol/L, P < 0.01], but there was no significant difference between moderate and severe patients(P > 0.05). The analysis of linear correlation showed that there was significant positive correlation between NO and PaO2 but not PaCO2.

CONCLUSIONAnoxia of patients with acute carbon monoxide poisoning may be an important cause to reduce NO level in blood. This study provides the basis for low NO concentration inhalation in treatments of acute carbon monoxide poisoning.

Acute Disease ; Carbon Dioxide ; blood ; Carbon Monoxide Poisoning ; blood ; Humans ; Nitric Oxide ; blood ; Oxygen ; blood

OBJECTIVEThe object of this study was to review the role of cardiac troponin as a prognostic factor in acute coronary syndrome patients of varying circumstances.

DATA SOURCESThe data used in this review were obtained mainly from the studies of cardiac troponin reported in pubmed from 1981 to 2006.

STUDY SELECTIONRelevant articles on studies of cardiac troponin were selected.

RESULTSElevated cardiac troponin in patients with ST elevation and non ST elevation myocardial infarction was associated with adverse outcomes, including a higher incidence of congestive heart failure, shock, and death. Patients with elevated cardiac troponin value seemed to benefit more from invasive strategies including a percutaneous coronary intervention and bypass surgery, but elevated cardiac troponin was also correlated with adverse outcomes, including a higher degree of failure, shock, and mortality in patients undergoing percutaneous coronary intervention; a higher degree of perioperative myocardial infarction, low cardiac output syndrome, cardiopulmonary resuscitation, and new-onset ventricular arrhythmia in patients undergoing bypass surgery were also observed. Elevated troponin after a percutaneous coronary intervention seemed to be associated with short-term adverse outcomes rather than long-term adverse outcomes, unless the elevation of the troponin post percutaneous coronary intervention was quite high (about 5 times above normal). On the contrary, elevated cardiac troponin after bypass surgery was more confusing to analyze since it happened in almost all patients. Furthermore, differences in cutoff values and time measurements in some studies add more confusion; thus, further research is warranted.

CONCLUSIONSThe prognostic value of cardiac troponin is demonstrated in almost all acute coronary syndrome patients. In addition to its high sensitivity and specificity, the prognostic value of cardiac troponin is another reason to make it the "golden cardiac marker" of this time.

Acute Coronary Syndrome ; blood ; therapy ; Biomarkers ; blood ; Humans ; Myocardial Infarction ; blood ; therapy ; Prognosis ; Troponin ; blood

BACKGROUND: Automated blood cell analyzers often read leukemic blasts as normal cells. In this study, we evaluated the 5-part differential patterns of blasts using automated analyzers to determine if they can differentiate among blast types. METHODS: Blood samples containing 10% or more blasts were collected from patients with acute leukemia (N=175). The 5-part differential count was conducted using DxH 800 (Beckman Coulter, USA) and XE-2100 analyzers (Sysmex Co., Japan), and the results were compared with manual differential counts, which was used as a reference method. RESULTS: The DxH 800 reported the 5-part white blood cell differential count in 98.9% of the cases. The XE-2100 provided an invalid automated differential count in 72% of the cases. Both analyzers counted most lymphoblasts as lymphocytes and most myeloblasts as monocytes. In 11 cases, the DxH 800 reported a 5-part differential count without a blast flag. CONCLUSIONS: Some automated analyzers are able to recognize and count blasts according to their characteristic cell types. Therefore, complete blood counts obtained automatically can provide valuable data for making provisional decisions regarding the lineage of leukemia cells before further investigation.
Acute Disease ; Automation ; Blood Cell Count/*instrumentation/methods ; Humans ; Leukemia/blood/*diagnosis ; Leukemia, Monocytic, Acute/blood/diagnosis ; Leukemia, Myeloid, Acute/blood/diagnosis ; Leukemia, Promyelocytic, Acute/blood/diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood/diagnosis

Acute Disease ; Acute Kidney Injury ; etiology ; Adolescent ; Humans ; Male ; Myoglobin ; blood ; Rhabdomyolysis ; complications

OBJECTIVEThis review discussed the available data on treatment outcomes of cord blood transplantation (CBT) for acute leukemia.

DATA SOURCESThe data cited in this review were obtained from articles listed in Medline and Pubmed.

STUDY SELECTIONWe reviewed the articles of clinical results from various registries and institutions, as well as our experiences with CBT in children, adolescents and adults.

RESULTSThis research has clearly shown that cord blood (CB) has several unique characteristics resulting in distinct advantage and disadvantages when compared to transplantation with unrelated donor bone marrow or peripheral blood stem cells. The field of CBT has advanced from investigating its safety and feasibility to addressing more specific issues such as accelerating engraftment, extending access, and examining outcomes in specific subgroups of patients. Many approaches have been investigated in the attempt to improve engraftment and survival. Variable factors have been identified, such as factors related to donor choice (human leukocyte antigen (HLA) compatibility, cell dose, and others) and transplantation (conditioning and graft-versus-host disease prophylaxis regimen). Data support that CB should be considered a reasonable option in those that do not have HLA matched sibling donor and for those in whom the time to transplant is critical.

CONCLUSIONSCB is a reasonable alternative to unrelated donor bone marrow or peripheral blood progenitor cells for transplantation. Recently developed strategies aimed at improving hematopoietic recovery and reducing early transplantation-related mortality could further improve treatment outcomes of CBT for patients with acute leukemia.

Acute Disease ; Fetal Blood ; transplantation ; Humans ; Leukemia ; therapy